We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Stryker (SYK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
The upcoming report from Stryker (SYK - Free Report) is expected to reveal quarterly earnings of $3.56 per share, indicating an increase of 11.6% compared to the year-ago period. Analysts forecast revenues of $6.58 billion, representing an increase of 8.6% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Stryker metrics that are commonly tracked and forecasted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Sales by Geography- Orthopaedics' will likely reach $2.88 billion. The estimate indicates a change of +28% from the prior-year quarter.
Analysts forecast 'Net Sales by Business- MedSurg and Neurotechnology' to reach $3.70 billion. The estimate suggests a change of -2.7% year over year.
Analysts' assessment points toward 'Net Sales by Business- MedSurg and Neurotechnology- Medical' reaching $1.13 billion. The estimate indicates a year-over-year change of +14.4%.
According to the collective judgment of analysts, 'Net Sales by Geography- Orthopaedics- Knees' should come in at $647.78 million. The estimate suggests a change of +3.2% year over year.
Based on the collective assessment of analysts, 'Net Sales by Geography- Orthopaedics- Trauma and Extremities' should arrive at $1.09 billion. The estimate indicates a year-over-year change of +13.1%.
Analysts expect 'Net Sales by Business- MedSurg and Neurotechnology- Instruments' to come in at $1.04 billion. The estimate suggests a change of +36.6% year over year.
Analysts predict that the 'Net Sales by Business- MedSurg and Neurotechnology- Endoscopy' will reach $1.02 billion. The estimate indicates a change of +13.9% from the prior-year quarter.
The average prediction of analysts places 'Net Sales by Geography- Orthopaedics- Hips' at $459.46 million. The estimate suggests a change of +0.5% year over year.
It is projected by analysts that the 'Net Sales by Geography- International' will reach $1.73 billion. The estimate points to a change of +16.4% from the year-ago quarter.
The consensus among analysts is that 'Net Sales by Geography- United States' will reach $4.85 billion. The estimate suggests a change of +6.1% year over year.
Over the past month, Stryker shares have recorded returns of +12.8% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #4 (Sell), SYK will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Countdown to Stryker (SYK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
The upcoming report from Stryker (SYK - Free Report) is expected to reveal quarterly earnings of $3.56 per share, indicating an increase of 11.6% compared to the year-ago period. Analysts forecast revenues of $6.58 billion, representing an increase of 8.6% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Stryker metrics that are commonly tracked and forecasted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Sales by Geography- Orthopaedics' will likely reach $2.88 billion. The estimate indicates a change of +28% from the prior-year quarter.
Analysts forecast 'Net Sales by Business- MedSurg and Neurotechnology' to reach $3.70 billion. The estimate suggests a change of -2.7% year over year.
Analysts' assessment points toward 'Net Sales by Business- MedSurg and Neurotechnology- Medical' reaching $1.13 billion. The estimate indicates a year-over-year change of +14.4%.
According to the collective judgment of analysts, 'Net Sales by Geography- Orthopaedics- Knees' should come in at $647.78 million. The estimate suggests a change of +3.2% year over year.
Based on the collective assessment of analysts, 'Net Sales by Geography- Orthopaedics- Trauma and Extremities' should arrive at $1.09 billion. The estimate indicates a year-over-year change of +13.1%.
Analysts expect 'Net Sales by Business- MedSurg and Neurotechnology- Instruments' to come in at $1.04 billion. The estimate suggests a change of +36.6% year over year.
Analysts predict that the 'Net Sales by Business- MedSurg and Neurotechnology- Endoscopy' will reach $1.02 billion. The estimate indicates a change of +13.9% from the prior-year quarter.
The average prediction of analysts places 'Net Sales by Geography- Orthopaedics- Hips' at $459.46 million. The estimate suggests a change of +0.5% year over year.
It is projected by analysts that the 'Net Sales by Geography- International' will reach $1.73 billion. The estimate points to a change of +16.4% from the year-ago quarter.
The consensus among analysts is that 'Net Sales by Geography- United States' will reach $4.85 billion. The estimate suggests a change of +6.1% year over year.
View all Key Company Metrics for Stryker here>>>Over the past month, Stryker shares have recorded returns of +12.8% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #4 (Sell), SYK will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .